When FIRSTPICK backed Emilė Radytė in 2021, her company Samphire Neuroscience was still building its first product and the risk, by the fund’s own assessment, was high. There was no revenue, no clear route to market, and a proposition, a neurotechnology wearable for menstrual pain, that most European investors would have politely declined to engage […]

This story continues at The Next Web